Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray.

Villa D, Tan KL, Steidl C, Ben-Neriah S, Al Moosawi M, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Scott DW, Gascoyne RD, Slack GW.

Blood Adv. 2019 Dec 10;3(23):3953-3961. doi: 10.1182/bloodadvances.2019000989.

PMID:
31805190
2.

Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing.

Laks E, McPherson A, Zahn H, Lai D, Steif A, Brimhall J, Biele J, Wang B, Masud T, Ting J, Grewal D, Nielsen C, Leung S, Bojilova V, Smith M, Golovko O, Poon S, Eirew P, Kabeer F, Ruiz de Algara T, Lee SR, Taghiyar MJ, Huebner C, Ngo J, Chan T, Vatrt-Watts S, Walters P, Abrar N, Chan S, Wiens M, Martin L, Scott RW, Underhill TM, Chavez E, Steidl C, Da Costa D, Ma Y, Coope RJN, Corbett R, Pleasance S, Moore R, Mungall AJ, Mar C, Cafferty F, Gelmon K, Chia S; CRUK IMAXT Grand Challenge Team, Marra MA, Hansen C, Shah SP, Aparicio S.

Cell. 2019 Nov 14;179(5):1207-1221.e22. doi: 10.1016/j.cell.2019.10.026.

3.

Mutational Landscape of Grey Zone Lymphoma.

Sarkozy C, Hung S, Takata K, Chavez E, Aoki T, Duns G, Slack GW, Telenius A, Miyata-Takata T, Viganò E, Molina TJ, Damotte D, Ben-Neriah S, Copie-Bergman C, Laurent C, Mottok A, Salles G, Savage KJ, Scott DW, Traverse-Glehen A, Steidl C.

Blood. 2019 Nov 13;134(Supplement_1):21. doi: 10.1182/blood-2019-127375.

PMID:
31724008
4.

Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity.

Nissen MD, Kusakabe M, Wang X, Simkin G, Gracias D, Tyshchenko K, Hill A, Meskas J, Hung S, Chavez EA, Ennishi D, Aoki T, Sarkozy C, Connors JM, Farinha P, Slack GW, Gascoyne RD, Brinkman RR, Scott DW, Steidl C, Weng AP.

Cytometry A. 2019 Oct 22. doi: 10.1002/cyto.a.23919. [Epub ahead of print]

PMID:
31637838
5.

Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling.

Zhang AW, O'Flanagan C, Chavez EA, Lim JLP, Ceglia N, McPherson A, Wiens M, Walters P, Chan T, Hewitson B, Lai D, Mottok A, Sarkozy C, Chong L, Aoki T, Wang X, Weng AP, McAlpine JN, Aparicio S, Steidl C, Campbell KR, Shah SP.

Nat Methods. 2019 Oct;16(10):1007-1015. doi: 10.1038/s41592-019-0529-1. Epub 2019 Sep 9.

PMID:
31501550
6.

Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.

Tobin JWD, Keane C, Gunawardana J, Mollee P, Birch S, Hoang T, Lee J, Li L, Huang L, Murigneux V, Fink JL, Matigian N, Vari F, Francis S, Kridel R, Weigert O, Haebe S, Jurinovic V, Klapper W, Steidl C, Sehn LH, Law SC, Wykes MN, Gandhi MK.

J Clin Oncol. 2019 Dec 1;37(34):3300-3309. doi: 10.1200/JCO.18.02365. Epub 2019 Aug 28.

PMID:
31461379
7.

Targeting GSK3: beyond the mitotic spindle?

Steidl C.

Blood. 2019 Jul 25;134(4):333-334. doi: 10.1182/blood.2019001638. No abstract available.

PMID:
31345924
8.

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.

Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, Meissner B, Nakamura H, Rushton C, Viganò E, Sarkozy C, Gascoyne RD, Connors JM, Ben-Neriah S, Mungall A, Marra MA, Siebert R, Scott DW, Savage KJ, Steidl C.

Blood. 2019 Sep 5;134(10):802-813. doi: 10.1182/blood.2019001126. Epub 2019 Jul 10.

PMID:
31292115
9.

Extubation Readiness in Critically Ill Stroke Patients.

Suntrup-Krueger S, Schmidt S, Warnecke T, Steidl C, Muhle P, Schroeder JB, Labeit B, Minnerup J, Dziewas R.

Stroke. 2019 Aug;50(8):1981-1988. doi: 10.1161/STROKEAHA.118.024643. Epub 2019 Jul 8.

PMID:
31280655
10.

Synthetic modeling reveals HOXB genes are critical for the initiation and maintenance of human leukemia.

Kusakabe M, Sun AC, Tyshchenko K, Wong R, Nanda A, Shanna C, Gusscott S, Chavez EA, Lorzadeh A, Zhu A, Hill A, Hung S, Brown S, Babaian A, Wang X, Holt RA, Steidl C, Karsan A, Humphries RK, Eaves CJ, Hirst M, Weng AP.

Nat Commun. 2019 Jul 2;10(1):2913. doi: 10.1038/s41467-019-10510-8.

11.

Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.

Costa S, Scott DW, Steidl C, Peacock SJ, Regier DA.

Curr Oncol. 2019 Apr;26(2):108-113. doi: 10.3747/co.26.4565. Epub 2019 Apr 1.

12.

Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.

Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, Sehn LH, Connors JM, Gascoyne RD, Feldman AL, Farinha P, Steidl C, Scott DW, Slack GW, Savage KJ.

Br J Haematol. 2019 Aug;186(3):e28-e31. doi: 10.1111/bjh.15860. Epub 2019 Mar 14. No abstract available.

PMID:
30873584
13.

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.

Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C.

Cancer Discov. 2019 Apr;9(4):546-563. doi: 10.1158/2159-8290.CD-18-1090. Epub 2019 Jan 31.

PMID:
30705065
14.

Convergence of risk prediction models in follicular lymphoma.

Silva A, Bassim S, Sarkozy C, Mottok A, Lackraj T, Jurinovic V, Brodtkorb M, Lingjaerde OC, Sehn LH, Gascoyne RD, Weigert O, Steidl C, Kridel R.

Haematologica. 2019 Jun;104(6):e252-e255. doi: 10.3324/haematol.2018.209031. Epub 2019 Jan 3. No abstract available.

15.

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW.

J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.

PMID:
30523716
16.

Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.

Sarkozy C, Copie-Bergman C, Damotte D, Ben-Neriah S, Burroni B, Cornillon J, Lemal R, Golfier C, Fabiani B, Chassagne-Clément C, Parrens M, Herbaux C, Xerri L, Bossard C, Laurent C, Cheminant M, Cartron G, Cabecadas J, Molina T, Salles G, Steidl C, Ghesquières H, Mottok A, Traverse-Glehen A.

Am J Surg Pathol. 2019 Mar;43(3):341-351. doi: 10.1097/PAS.0000000000001198.

PMID:
30540571
17.

Identification of TRA-1-60-positive cells as a potent refractory population in follicular lymphomas.

Takata K, Saito K, Maruyama S, Miyata-Takata T, Iioka H, Okuda S, Ling Y, Karube K, Miki Y, Maeda Y, Yoshino T, Steidl C, Kondo E.

Cancer Sci. 2019 Jan;110(1):443-457. doi: 10.1111/cas.13870. Epub 2018 Dec 8.

18.

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, Collinge B, Abrisqueta P, Farinha P, Boyle M, Meissner B, Kridel R, Gerrie AS, Villa D, Savage KJ, Sehn LH, Siebert R, Morin RD, Gascoyne RD, Marra MA, Connors JM, Mungall AJ, Steidl C, Scott DW.

Blood Adv. 2018 Oct 23;2(20):2755-2765. doi: 10.1182/bloodadvances.2018023572.

19.

Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.

Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD.

Nat Commun. 2018 Oct 1;9(1):4001. doi: 10.1038/s41467-018-06354-3.

20.

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM.

Blood. 2018 Nov 29;132(22):2401-2405. doi: 10.1182/blood-2018-05-851154. Epub 2018 Sep 26.

21.

Novel Biomarker Approaches in Classic Hodgkin Lymphoma.

Aoki T, Steidl C.

Cancer J. 2018 Sep/Oct;24(5):206-214. doi: 10.1097/PPO.0000000000000334. Review.

PMID:
30247255
22.

JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.

Schuhmacher B, Bein J, Rausch T, Benes V, Tousseyn T, Vornanen M, Ponzoni M, Thurner L, Gascoyne R, Steidl C, Küppers R, Hansmann ML, Hartmann S.

Haematologica. 2019 Feb;104(2):330-337. doi: 10.3324/haematol.2018.203224. Epub 2018 Sep 13.

23.

Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis.

Gragnani L, Cerretelli G, Lorini S, Steidl C, Giovannelli A, Monti M, Petraccia L, Sadalla S, Urraro T, Caini P, Xheka A, Simone A, Arena U, Matucci-Cerinic M, Vergani D, Laffi G, Zignego AL.

Aliment Pharmacol Ther. 2018 Aug;48(4):440-450. doi: 10.1111/apt.14845. Epub 2018 Jun 28.

PMID:
29952013
24.

Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.

Mottok A, Steidl C.

Blood. 2018 Apr 12;131(15):1654-1665. doi: 10.1182/blood-2017-09-772632. Epub 2018 Mar 2. Review.

PMID:
29500175
25.

Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation.

Viganò E, Gunawardana J, Mottok A, Van Tol T, Mak K, Chan FC, Chong L, Chavez E, Woolcock B, Takata K, Twa D, Shulha HP, Telenius A, Kutovaya O, Hung SS, Healy S, Ben-Neriah S, Leroy K, Gaulard P, Diepstra A, Kridel R, Savage KJ, Rimsza L, Gascoyne R, Steidl C.

Blood. 2018 May 3;131(18):2036-2046. doi: 10.1182/blood-2017-09-808907. Epub 2018 Feb 21.

PMID:
29467182
26.

Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation.

Osswald CD, Xie L, Guan H, Herrmann F, Pick SM, Vogel MJ, Gehringer F, Chan FC, Steidl C, Wirth T, Ushmorov A.

Blood. 2018 Apr 5;131(14):1556-1567. doi: 10.1182/blood-2017-07-795278. Epub 2018 Feb 13.

27.

Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.

Hung SS, Meissner B, Chavez EA, Ben-Neriah S, Ennishi D, Jones MR, Shulha HP, Chan FC, Boyle M, Kridel R, Gascoyne RD, Mungall AJ, Marra MA, Scott DW, Connors JM, Steidl C.

J Mol Diagn. 2018 Mar;20(2):203-214. doi: 10.1016/j.jmoldx.2017.11.010. Epub 2018 Feb 8.

PMID:
29429887
28.

Novel insights into the disease dynamics of B-cell lymphomas in the Genomics Era.

Chan FC, Lim E, Kridel R, Steidl C.

J Pathol. 2018 Apr;244(5):598-609. doi: 10.1002/path.5043. Epub 2018 Mar 6. Review.

PMID:
29359812
29.

The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.

Twa DDW, Mottok A, Savage KJ, Steidl C.

Blood Rev. 2018 May;32(3):249-255. doi: 10.1016/j.blre.2017.12.001. Epub 2017 Dec 20. Review.

PMID:
29289361
30.

The ecosystem of classical Hodgkin lymphoma.

Steidl C.

Blood. 2017 Nov 30;130(22):2360-2361. doi: 10.1182/blood-2017-10-807172. No abstract available.

PMID:
29191975
31.

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R.

Blood. 2018 Jan 11;131(2):226-235. doi: 10.1182/blood-2017-08-799080. Epub 2017 Nov 9.

32.

Observation as the initial management strategy in patients with mantle cell lymphoma.

Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D.

Ann Oncol. 2017 Oct 1;28(10):2489-2495. doi: 10.1093/annonc/mdx333.

PMID:
28961827
33.

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.

Chan FC, Mottok A, Gerrie AS, Power M, Nijland M, Diepstra A, van den Berg A, Kamper P, d'Amore F, d'Amore AL, Hamilton-Dutoit S, Savage KJ, Shah SP, Connors JM, Gascoyne RD, Scott DW, Steidl C.

J Clin Oncol. 2017 Nov 10;35(32):3722-3733. doi: 10.1200/JCO.2017.72.7925. Epub 2017 Sep 12.

PMID:
28898161
34.

Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma.

Li PC, Siddiqi IN, Mottok A, Loo EY, Wu CH, Cozen W, Steidl C, Shih JC.

J Pathol. 2017 Oct;243(2):220-229. doi: 10.1002/path.4944. Epub 2017 Sep 5.

35.

Automated high throughput nucleic acid purification from formalin-fixed paraffin-embedded tissue samples for next generation sequence analysis.

Haile S, Pandoh P, McDonald H, Corbett RD, Tsao P, Kirk H, MacLeod T, Jones M, Bilobram S, Brooks D, Smailus D, Steidl C, Scott DW, Bala M, Hirst M, Miller D, Moore RA, Mungall AJ, Coope RJ, Ma Y, Zhao Y, Holt RA, Jones SJ, Marra MA.

PLoS One. 2017 Jun 1;12(6):e0178706. doi: 10.1371/journal.pone.0178706. eCollection 2017.

36.

Tracheostomy, Extubation, Reintubation: Airway Management Decisions in Intubated Stroke Patients.

Steidl C, Bösel J, Suntrup-Krueger S, Schönenberger S, Al-Suwaidan F, Warnecke T, Minnerup J, Dziewas R; Initiative for German Neuro-Intensive Trial Engagement (IGNITE).

Cerebrovasc Dis. 2017;44(1-2):1-9. doi: 10.1159/000471892. Epub 2017 Apr 11. Erratum in: Cerebrovasc Dis. 2017;44(1-2):9.

PMID:
28395275
37.

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.

Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R, Lai D, Saberi S, Bashashati A, Shah SP, Morin RD, Marra MA, Savage KJ, Sehn LH, Steidl C, Connors JM, Gascoyne RD, Scott DW.

Blood. 2017 May 18;129(20):2760-2770. doi: 10.1182/blood-2016-11-747022. Epub 2017 Mar 28.

PMID:
28351934
38.

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project.

J Clin Oncol. 2017 May 20;35(15):1668-1677. doi: 10.1200/JCO.2016.70.7901. Epub 2017 Mar 14.

39.

Exposing Hodgkin-Reed-Sternberg cells.

Steidl C.

Blood. 2017 Jan 5;129(1):6-7. doi: 10.1182/blood-2016-11-746701. No abstract available.

PMID:
28057670
40.

Defining the clonality of peripheral T cell lymphomas using RNA-seq.

Brown SD, Hapgood G, Steidl C, Weng AP, Savage KJ, Holt RA.

Bioinformatics. 2017 Apr 15;33(8):1111-1115. doi: 10.1093/bioinformatics/btw810.

41.

Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.

Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP.

PLoS Med. 2016 Dec 13;13(12):e1002197. doi: 10.1371/journal.pmed.1002197. eCollection 2016 Dec.

42.

A time-and-motion approach to micro-costing of high-throughput genomic assays.

Costa S, Regier DA, Meissner B, Cromwell I, Ben-Neriah S, Chavez E, Hung S, Steidl C, Scott DW, Marra MA, Peacock SJ, Connors JM.

Curr Oncol. 2016 Oct;23(5):304-313. Epub 2016 Oct 25.

43.

Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them.

Savage KJ, Steidl C.

Expert Rev Hematol. 2016 Nov;9(11):1007-1009. Epub 2016 Oct 17. No abstract available.

PMID:
27677541
44.

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, Romano A, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA.

Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.

PMID:
27692305
45.

Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.

Chong LC, Twa DD, Mottok A, Ben-Neriah S, Woolcock BW, Zhao Y, Savage KJ, Marra MA, Scott DW, Gascoyne RD, Morin RD, Mungall AJ, Steidl C.

Blood. 2016 Sep 1;128(9):1206-13. doi: 10.1182/blood-2015-11-683003. Epub 2016 Jun 7.

PMID:
27268263
46.

Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction.

Talhouk A, Kommoss S, Mackenzie R, Cheung M, Leung S, Chiu DS, Kalloger SE, Huntsman DG, Chen S, Intermaggio M, Gronwald J, Chan FC, Ramus SJ, Steidl C, Scott DW, Anglesio MS.

PLoS One. 2016 Apr 20;11(4):e0153844. doi: 10.1371/journal.pone.0153844. eCollection 2016.

47.

Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro.

Leung AW, Hung SS, Backstrom I, Ricaurte D, Kwok B, Poon S, McKinney S, Segovia R, Rawji J, Qadir MA, Aparicio S, Stirling PC, Steidl C, Bally MB.

PLoS One. 2016 Mar 3;11(3):e0150675. doi: 10.1371/journal.pone.0150675. eCollection 2016.

48.

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.

Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD.

Blood. 2016 May 5;127(18):2182-8. doi: 10.1182/blood-2015-10-676700. Epub 2016 Feb 1.

PMID:
26834242
49.

Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.

Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, Simone PD, Zhang W, Gong Q, Wang C, Cannon A, Heavican T, Mottok A, Hung S, Rosenwald A, Gascoyne R, Fu K, Greiner TC, Weisenburger DD, Vose JM, Staudt LM, Xiao W, Borgstahl GE, Davis S, Steidl C, McKeithan T, Iqbal J, Chan WC.

Leukemia. 2016 May;30(5):1062-70. doi: 10.1038/leu.2015.357. Epub 2015 Dec 31.

50.

Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.

Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, Telenius A, Chavez E, Ramchandani S, Drake M, Boyle M, Ben-Neriah S, Scott DW, Rimsza LM, Siebert R, Gascoyne RD, Steidl C.

Cell Rep. 2015 Nov 17;13(7):1418-1431. doi: 10.1016/j.celrep.2015.10.008. Epub 2015 Nov 5.

Supplemental Content

Loading ...
Support Center